Abstract
The contemporary American food environment makes energy-dense, nutrient-poor foods and beverages the “default” option for most consumers. Economic interventions like taxes can shift the relative prices of unhealthy foods to nudge consumers towards healthier options. Beverages with added sugar are a good starting point for food taxation; they constitute over 10 percent of caloric intake nationwide and provide little or no nutritional value. Current levels of taxation on sugar-sweetened beverages (SSBs) are too low to affect consumer behavior, but the implementation of a penny-per-ounce excise tax could lead to substantial public health benefits. Current estimates predict that a tax that raised the cost of SSBs by 20 percent could lead to an average reduction of 3.8 pounds per year for adults, causing the prevalence of obesity to decline from 33 to 30 percent. SSB taxes would also generate considerable revenue for public health and obesity prevention programs. Although the beverage industry is fighting such taxes with massive lobbying and public relations campaigns, support for the policies is increasing, especially when revenue is earmarked for obesity prevention.
Keywords: Sugar-sweetened beverages, soda, obesity, taxation, prevention, retina, Sugar-sweetened, gratification, overweight, grassroots, calories, consumption, synergistic, environment, Beverages, implementation, energy
Current Pharmaceutical Design
Title: Taxation as Prevention and as a Treatment for Obesity: The Case of Sugar-Sweetened Beverages
Volume: 17 Issue: 12
Author(s): Nicole L. Novak and Kelly D. Brownell
Affiliation:
Keywords: Sugar-sweetened beverages, soda, obesity, taxation, prevention, retina, Sugar-sweetened, gratification, overweight, grassroots, calories, consumption, synergistic, environment, Beverages, implementation, energy
Abstract: The contemporary American food environment makes energy-dense, nutrient-poor foods and beverages the “default” option for most consumers. Economic interventions like taxes can shift the relative prices of unhealthy foods to nudge consumers towards healthier options. Beverages with added sugar are a good starting point for food taxation; they constitute over 10 percent of caloric intake nationwide and provide little or no nutritional value. Current levels of taxation on sugar-sweetened beverages (SSBs) are too low to affect consumer behavior, but the implementation of a penny-per-ounce excise tax could lead to substantial public health benefits. Current estimates predict that a tax that raised the cost of SSBs by 20 percent could lead to an average reduction of 3.8 pounds per year for adults, causing the prevalence of obesity to decline from 33 to 30 percent. SSB taxes would also generate considerable revenue for public health and obesity prevention programs. Although the beverage industry is fighting such taxes with massive lobbying and public relations campaigns, support for the policies is increasing, especially when revenue is earmarked for obesity prevention.
Export Options
About this article
Cite this article as:
L. Novak Nicole and D. Brownell Kelly, Taxation as Prevention and as a Treatment for Obesity: The Case of Sugar-Sweetened Beverages, Current Pharmaceutical Design 2011; 17(12) . https://dx.doi.org/10.2174/138161211795656783
DOI https://dx.doi.org/10.2174/138161211795656783 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Lifestyle, Maternal Nutrition and Healthy Pregnancy
Current Vascular Pharmacology Nifedipine Induced Gingival Hyperplasia in Pregnancy: A Case Report
Current Drug Safety Cognitive Dysfunction in Depression: Lessons Learned from Animal Models
CNS & Neurological Disorders - Drug Targets Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Oxidative Stress in Polycystic Ovary Syndrome
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor γ Agonists as Insulin Sensitizers: From the Discovery to Recent Progress
Current Topics in Medicinal Chemistry Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews Treatment of ‘Diabesity’: Beyond Pharmacotherapy
Current Drug Targets Application of Aptamer-based Hybrid Molecules in Early Diagnosis and Treatment of Diabetes Mellitus: From the Concepts Towards the Future
Current Diabetes Reviews Impact of Mixed Nonionic Surfactants on Self-Nanoemulsification Efficiency of Sefsol-218 in Glibenclamide Nanoemulsion
Current Nanoscience Quantitative Evaluation of Diabetic Medical Record Documentation
Current Diabetes Reviews Physico-Chemical Properties Mediating Reproductive and Developmental Toxicity of Engineered Nanomaterials
Current Medicinal Chemistry Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine Relationships of Beta2- and Beta3--Adrenoceptor Polymorphisms with Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research